Salix Pharmaceuticals Ltd.
- SLXP
- NASDAQ
- Consumer Products
- Latest 59.28
- Currency US$
- Change 0.09
- Percent Change 0.152 %
- Volume 420,834
- Fri May 17, 2013 4:00 PM EDT NASDAQ data delayed 15 minutes.
The Globe and Mail
- Open 59.40
- Previous Close 59.19
- High 59.56
- Low 58.75
- Bidx0 --
- Askx0 --
- 52-week High 05/15 60.20
- 52-week Low 11/07 37.52
- Beta 0.706
- Market Cap 3,488.04M
- EPS 1.31
- P/E 45.25
- Forward P/E 12.972
- PEG 1.01
- Annual Dividend --
- Yield --
News
- Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2013
- Salix Pharmaceuticals Reports 1Q2013 Results
- Salix Pharmaceuticals to Present at BofA Merrill Lynch 2013 Health Care Conference
- Salix Pharmaceuticals Announces 1Q2013 Financial Results Conference Call and Webcast
- Salix Pharmaceuticals Reports 4Q2012 and FY2012 Results
Financials & Calendars
- Sales $735,440,000
- Earnings $63,620,000
- Return on Equity 11.64%
- Cash Flow --
- Cash $751,000,000
- Current Ratio 4.56
12 months ended Dec 31, 2012.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $1,874,780,000
- Liabilities $1,314,280,000
- Liabilities-to-Equity Ratio 2.34
Price Ratios
- Price to Sales 4.74
- Price to Book 6.22
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | May 9 | $0.55 | Aug 7 | $0.82 |
| Surprises | May 9 | 3.64% | n/a | n/a |
| Dividends | n/a | n/a | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 18, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Salix Pharmaceuticals, Ltd. objective is to be a market-driven specialty pharmaceutical company focussed on the needs of physicians specializing in gastroenterology. The company intends to establish a small direct sales force to promote its products to this specialist audience. The company's strategy is to identify and acquire products that have near-term commercial potential and apply its regulatory and product development expertise to commercialize these products. The company selects products that it believes serve a gastrointestinal disease.
Officers
- Thomas W. D'Alonzo Chairman of the Board
- Carolyn J. Logan President; Chief Executive Off
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
8510 COLONNADE CENTER DRIVERALEIGH, NC
27615
Phone: 9198621000
Ideas & Discussion
Live Discussion of SLXP on StockTwits